<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670241</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80185-G21</org_study_id>
    <nct_id>NCT00670241</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris</brief_title>
  <official_title>A Phase 3 Study Comparing a Gel Containing Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) With Tacalcitol Ointment (4 mcg/g) and Gel Vehicle, Used Once Daily in the Treatment of Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare efficacy and safety of once daily treatment of calcipotriol plus
      betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle
      alone in subjects with psoriasis vulgaris. Subjects will be treated for up to 8 weeks
      followed by an observation period of up to 8 weeks to investigate the occurence and the time
      to relapse and occurence of rebound after discontinuation of the investigational products.
      Only subjects with &quot;controlled disease&quot; will be considered for this observation phase of the
      study. &quot;Controlled disease&quot; is defined as &quot;Clear&quot; or &quot;Almost Clear&quot; severity category based
      on Investigator's global assessment (IGA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With &quot;Controlled Disease&quot; (&quot;Clear&quot; or &quot;Almost Clear&quot; Disease) According to Investigator's Global Assessment of Disease Severity at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment of Disease Severity at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change in PASI From Baseline to Week 8</measure>
    <time_frame>Baseline, Week 4 and 8</time_frame>
    <description>PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Relapse During the Study</measure>
    <time_frame>Week 8-16</time_frame>
    <description>Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Rebound During the Study</measure>
    <time_frame>Week 8-16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcipotriol and betamethasone (LEO 80185 gel)</intervention_name>
    <description>Once daily application</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185 vehicle</intervention_name>
    <description>Once daily application</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacalcitol ointment</intervention_name>
    <description>Once daily application</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent to be obtained prior to any trial related procedure,
             including wash-out

          -  Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs
             amenable to treatment with a maximum of 100 g of LEO 80185 gel per week or 10 g per
             day of tacalcitol ointment

          -  Disease severity graded moderate, severe or very severe according to the
             Investigator's global assessment (IGA) of disease severity

          -  A minimum PASI score for extent of 2 in at least one body region (i.e.psoriasis
             affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs)

          -  Subjects aged 18 years or above

          -  Either sex

          -  Any ethnic origin

          -  Attending hospital outpatient clinic or the private practice of a dermatologist

        Exclusion Criteria:

          -  Systemic treatment with biological therapies (marketed or not marketed), with a
             possible effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept,
             infliximab, adalimumab) within 3 months prior to randomisation

          -  Systemic treatment with all other therapies than biologics, with a possible effect on
             psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 4
             weeks prior to randomisation

          -  Systemic treatment with Vitamin D preparations above 500 IU per day

          -  PUVA or Grenz ray therapy within 4 weeks prior to randomization

          -  UVB therapy within 2 weeks prior to randomisation

          -  Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior
             to randomisation

          -  Topical treatment for other relevant skin disorders on the face and flexures (e.g.,
             facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV)
             corticosteroids or vitamin D analogues within 2 weeks prior to randomisation

          -  Topical treatment for other relevant skin disorders on the scalp (e.g. scalp
             psoriasis) with very potent (WHO group IV) corticosteroids or vitamin D analogues
             within 2 weeks prior to randomisation

          -  Planned initiation of, or changes to concomitant medication that could affect
             psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium)
             during the study

          -  Current diagnosis of erythrodermic, exfoliative or pustular psoriasis

          -  Subjects with any of the following conditions present on the treatment area: viral
             (e.g., herpes or varicella) lesions, fungal and bacterial skin infections, parasitic
             infections, skin manifestations in relation to syphilis or tuberculosis, rosacea,
             perioral dermatitis, acne vulgaris, atrophic skin, striae atro-phicae, fragility of
             skin veins, ichthyosis, acne rosacea, ulcers and wounds

          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Known or suspected hypersensitivity to component(s) of the Investigational Products

          -  Current participation in any other interventional clinical study

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. an
             agent which has not yet been made available for clinical use following registration)
             within the 4-week period prior to randomisation, except for biologics (3 months)

          -  Planned exposure to sun during the study that may affect psoriasis vulgaris

          -  Previously randomised to this study

          -  Subjects known or suspected of not being able to comply with a trial protocol (e.g.
             due to alcoholism, drug dependency or psychotic state)

          -  Females of child-bearing potential wishing to become pregnant during the study, or are
             breast-feeding, or not using an adequate method of contraception during the study

          -  Females of child-bearing potential with positive pregnancy test at Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Langley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Canada Cutaneous Research Associates Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <results_first_submitted>November 23, 2010</results_first_submitted>
  <results_first_submitted_qc>February 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2011</results_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>1 alpha,24-dihydroxyvitamin D3</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
          <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Tacalcitol Ointment</title>
          <description>Tacalcitol Ointment for up to 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Gel Vehicle</title>
          <description>Gel Vehicle for up to 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
          <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Tacalcitol Ointment</title>
          <description>Tacalcitol Ointment for up to 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Gel Vehicle</title>
          <description>Gel Vehicle for up to 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="91"/>
            <count group_id="B4" value="458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="14.3"/>
                    <measurement group_id="B2" value="51.7" spread="13.4"/>
                    <measurement group_id="B3" value="52.8" spread="14.9"/>
                    <measurement group_id="B4" value="51.6" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With &quot;Controlled Disease&quot; (&quot;Clear&quot; or &quot;Almost Clear&quot; Disease) According to Investigator's Global Assessment of Disease Severity at Week 8</title>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
            <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tacalcitol Ointment</title>
            <description>Tacalcitol Ointment for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Gel Vehicle for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With &quot;Controlled Disease&quot; (&quot;Clear&quot; or &quot;Almost Clear&quot; Disease) According to Investigator's Global Assessment of Disease Severity at Week 8</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>5.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment of Disease Severity at Week 4</title>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
            <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tacalcitol Ointment</title>
            <description>Tacalcitol Ointment for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Gel Vehicle for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment of Disease Severity at Week 4</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.51</param_value>
            <ci_percent>98.33</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>8.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change in PASI From Baseline to Week 8</title>
        <description>PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).</description>
        <time_frame>Baseline, Week 4 and 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
            <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tacalcitol Ointment</title>
            <description>Tacalcitol Ointment for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Gel Vehicle for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in PASI From Baseline to Week 8</title>
          <description>PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).</description>
          <units>Percent change in PASI score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.0"/>
                    <measurement group_id="O2" value="-41.9"/>
                    <measurement group_id="O3" value="-17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.7</param_value>
            <ci_percent>98.33</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>-6.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Relapse During the Study</title>
        <description>Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit</description>
        <time_frame>Week 8-16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
            <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tacalcitol Ointment</title>
            <description>Tacalcitol Ointment for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Gel Vehicle for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Relapse During the Study</title>
          <description>Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Rebound During the Study</title>
        <time_frame>Week 8-16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
            <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tacalcitol Ointment</title>
            <description>Tacalcitol Ointment for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Gel Vehicle</title>
            <description>Gel Vehicle for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Rebound During the Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Calcipotriol Plus Betamethasone Dipropionate Gel</title>
          <description>Calcipotriol Plus Betamethasone Dipropionate Gel for up to 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Tacalcitol Ointment</title>
          <description>Tacalcitol Ointment for up to 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Gel Vehicle</title>
          <description>Gel Vehicle for up to 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anders Rhod Larsen, Scientific Advisor</name_or_title>
      <organization>LEO Pharma</organization>
      <phone>+4572262990</phone>
      <email>anders.larsen@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

